• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射3克剂量头孢曲松后的药代动力学。

Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

作者信息

McNamara P J, Stoeckel K, Ziegler W H

出版信息

Eur J Clin Pharmacol. 1982;22(1):71-5. doi: 10.1007/BF00606428.

DOI:10.1007/BF00606428
PMID:6284519
Abstract

The pharmacokinetic parameters of total (bound and unbound) and free (unbound) ceftriaxone in six healthy volunteers after intravenous injection of 39 were compared with low-dose data from a previous study. The dose-dependent behaviour of total drug was considerably more pronounced after the 3 gram dose. In contrast, total body clearance (C1FS = 258 ml/Min), renal clearance (C1FR = 170 ml/min) and volume of distribution (VFD (beta) = 168 1) of free (unbound) drug did not differ from the data reported earlier. There was no significant change in biological half-life (t1/2 (beta) = 7.8 h) or in the fraction excreted unchanged in urine (fu = 0.67).

摘要

将39静脉注射后,对6名健康志愿者体内总(结合型和非结合型)头孢曲松和游离(非结合型)头孢曲松的药代动力学参数与先前一项研究的低剂量数据进行了比较。3克剂量后,总药物的剂量依赖性行为更为明显。相比之下,游离(非结合型)药物的总体清除率(C1FS = 258毫升/分钟)、肾清除率(C1FR = 170毫升/分钟)和分布容积(VFD(β) = 168升)与先前报道的数据没有差异。生物半衰期(t1/2(β) = 7.8小时)或尿中以原形排泄的分数(fu = 0.67)没有显著变化。

相似文献

1
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.静脉注射3克剂量头孢曲松后的药代动力学。
Eur J Clin Pharmacol. 1982;22(1):71-5. doi: 10.1007/BF00606428.
2
Single-dose pharmacokinetics of ceftriaxone in infants and young children.头孢曲松在婴幼儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1982 Feb;21(2):248-53. doi: 10.1128/AAC.21.2.248.
3
Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration.头孢曲松皮下注射和静脉注射后的比较药代动力学
Chemotherapy. 1985;31(4):237-45. doi: 10.1159/000238342.
4
Pharmacokinetics of ceftriaxone in humans.头孢曲松在人体内的药代动力学。
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.
5
Single-dose ceftriaxone kinetics in the newborn.新生儿单剂量头孢曲松的动力学
Clin Pharmacol Ther. 1985 May;37(5):522-8. doi: 10.1038/clpt.1985.82.
6
The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.头孢噻肟及其代谢产物的人体药代动力学以及肾小管分泌在其消除过程中的作用。
J Pharmacokinet Biopharm. 1985 Apr;13(2):121-42. doi: 10.1007/BF01059394.
7
Cefodizime penetration into skin suction blister fluid following a single intravenous dose.单次静脉给药后头孢地嗪在皮肤抽吸水疱液中的渗透情况。
Eur J Clin Pharmacol. 1986;30(3):295-8. doi: 10.1007/BF00541531.
8
Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.头孢曲松的药代动力学及其与血管外腔室浓度的关系。与头孢噻肟的比较。
Chemotherapy. 1985;31(2):85-94. doi: 10.1159/000238319.
9
Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep.头孢尼西、头孢曲松和头孢哌酮在绵羊体内的药代动力学
J Vet Pharmacol Ther. 1985 Jun;8(2):120-7. doi: 10.1111/j.1365-2885.1985.tb00935.x.
10
Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.正常成年人静脉注射头孢曲松的药代动力学特征。
Antimicrob Agents Chemother. 1982 Nov;22(5):816-23. doi: 10.1128/AAC.22.5.816.

引用本文的文献

1
Acute pancreatitis caused by ceftriaxone-associated biliary pseudolithiasis in an older patient: A case report and literature review.老年患者中头孢曲松相关胆源性假性结石引起的急性胰腺炎:一例报告及文献复习
Radiol Case Rep. 2025 May 23;20(8):3977-3981. doi: 10.1016/j.radcr.2025.04.124. eCollection 2025 Aug.
2
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.基于生理的头孢曲松在健康人群和慢性肾病患者中单剂量和多剂量给药方案的药代动力学建模:一种模型指导精准给药的工具。
Front Pharmacol. 2023 Jul 20;14:1200828. doi: 10.3389/fphar.2023.1200828. eCollection 2023.
3

本文引用的文献

1
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.浓度依赖性血浆蛋白结合对头孢曲松动力学的影响。
Clin Pharmacol Ther. 1981 May;29(5):650-7. doi: 10.1038/clpt.1981.90.
2
Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.Ro 13-9904,一种长效广谱头孢菌素:体外和体内研究
Antimicrob Agents Chemother. 1980 Dec;18(6):913-21. doi: 10.1128/AAC.18.6.913.
3
Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.Ro 13-9904/001,一种新型强效长效肠胃外注射用头孢菌素。
Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients.
精准剂量,即刻给药:开发自动动力学以实现基于实时模型的重症患者床边精准抗生素给药决策支持。
Front Pharmacol. 2020 May 15;11:646. doi: 10.3389/fphar.2020.00646. eCollection 2020.
4
Ceftriaxone-associated nephrolithiasis and gallstone in adults.成人中与头孢曲松相关的肾结石和胆结石
Drug Healthc Patient Saf. 2018 Dec 12;10:103-108. doi: 10.2147/DHPS.S183892. eCollection 2018.
5
A case of ceftriaxone-associated biliary pseudolithiasis in an elderly patient with renal dysfunction.一例老年肾功能不全患者头孢曲松相关的胆汁假性结石病例。
IDCases. 2017 Jun 27;9:62-64. doi: 10.1016/j.idcr.2017.06.007. eCollection 2017.
6
Acute cholecystitis caused by ceftriaxone stones in an adult.成人头孢曲松结石所致急性胆囊炎
Case Rep Med. 2009;2009:132452. doi: 10.1155/2009/132452. Epub 2009 Apr 26.
7
Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.急性坏死性胆囊炎:头孢曲松相关假结石症的一种罕见并发症。
Pediatr Surg Int. 2006 Jun;22(6):562-4. doi: 10.1007/s00383-006-1656-1. Epub 2006 Feb 17.
8
PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.PKQuest:毛细血管通透性限制与血浆蛋白结合——应用于人体菊粉、双氯西林和头孢曲松的药代动力学
BMC Clin Pharmacol. 2002 Sep 26;2:7. doi: 10.1186/1472-6904-2-7.
9
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.头孢曲松:其在社区获得性感染和医院感染管理中应用的最新情况
Drugs. 2002;62(7):1041-89. doi: 10.2165/00003495-200262070-00005.
10
Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.单次静脉注射0.5克、1.0克、2.0克和3.0克头孢地嗪后,健康志愿者体内的药代动力学情况。
Antimicrob Agents Chemother. 1995 Sep;39(9):2037-41. doi: 10.1128/AAC.39.9.2037.
J Antibiot (Tokyo). 1980 Jul;33(7):783-6. doi: 10.7164/antibiotics.33.783.
4
Single-dose pharmacokinetics of cefoperazone following intravenous administration.
Clin Ther. 1980;3(Spec Issue):46-9.
5
Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.头孢噻肟与拉氧头孢的药代动力学及组织浓度比较。
Antimicrob Agents Chemother. 1980 Sep;18(3):369-71. doi: 10.1128/AAC.18.3.369.
6
Comparative pharmacokinetics of cefoperazone and cefotaxime.
Clin Ther. 1980;3(Spec Issue):80-8.
7
Pharmacokinetics and clinical use of cephalosporin antibiotics.头孢菌素类抗生素的药代动力学及临床应用
J Pharm Sci. 1975 Dec;64(12):1899-926. doi: 10.1002/jps.2600641202.
8
[Pharmacokinetics of a new cephalosporin, cefoperazone].
Schweiz Med Wochenschr. 1979 Dec 29;109(50):1999-2005.
9
Human pharmacology of cefotaxime (HR 756), a new cephalosporin.新型头孢菌素头孢噻肟(HR 756)的人体药理学
Antimicrob Agents Chemother. 1979 Aug;16(2):127-33. doi: 10.1128/AAC.16.2.127.